Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified
Abstract Acute leukemias of ambiguous lineage, not otherwise specified (ALAL-NOS) is a rare type of acute leukemia. Management of relapse/refractory (R/R) patients is still challenging.traditional chemotherapy treatment is not effective. In this paper, we reported 6 R/R patients diagnosed as ALAL-NO...
Main Authors: | Kaiqi Liu, Yan Li, Shaowei Qiu, Chunlin Zhou, Shuning Wei, Dong Lin, Guangji Zhang, Hui Wei, Ying Wang, Bingcheng Liu, Xiaoyuan Gong, Qiuyun Fang, Yang Song, Huijun Wang, Chengwen Li, Qinghua Li, Lihua Wu, Benfa Gong, Yuntao Liu, Jianxiang Wang, Yingchang Mi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-09-01
|
Series: | Experimental Hematology & Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40164-021-00239-w |
Similar Items
-
Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
by: Stefanie Jilg, et al.
Published: (2019-04-01) -
MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
by: Deepak Kumar Shukla, et al.
Published: (2021-01-01) -
Concurrent diagnosis of acute myeloid leukemia and symptomatic COVID-19 infection: a case report successfully treated with Azacitidine-Venetoclax combination
by: Daniela Taurino, et al.
Published: (2021-08-01) -
Venetoclax: evidence to date and clinical potential
by: Luis Miguel Juárez-Salcedo, et al.
Published: (2019-10-01) -
VENETOCLAX IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (literature review)
by: T. E. Byalik
Published: (2018-07-01)